Drug intelligence / Profile preview

iDD005

Development stage: Preclinical
Lead developer: InduPro
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**iDD005** (also referred to as IDP 005) is a **bispecific antibody-drug conjugate (ADC)** developed by **InduPro** using their proprietary **MInt™ platform** and by **iDD biotech** through licensing of antibodies and patents related to CK8 from Pulsalys. It is designed for the **treatment of cancer**, leveraging its bispecific ADC modality to target tumor cells with enhanced specificity and potency. The MInt™ platform enables multi-specific binding capabilities, potentially improving efficacy and safety profiles in oncology indications.[1][4][20]

Other names: IDP 005IDP005IDP-005

Beyond the preview

Go deeper on iDD005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iDD005.

Explore the full profile